## INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT NARCOLEPSY AGENTS PRIOR AUTHORIZATION REQUEST FORM



## MDwise Fax to: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department 10181 Scripps Gateway Court, San Diego, CA 92131 Phone: (800) 788-2949



(HORAL)		Phone: (800) 788	-2949	
Today's Date     /   /     Note: This form must be comple **Al			the request will be retu	urned**
Patient's Medicaid#		<del></del>	e of Birth	//
Patient's Name			Prescriber's Name	
Prescriber's IN License#			Specialty	
Prescriber's NPI#		Pres	Prescriber's Signature	
Return Fax # -			Return Phone #	
Check box if requesting retro-active PA			Date(s) of service requested for retro-active eligibility (if applicable):	
Note: Submit PA requests for retroact imelines) with dates of service prior that all ays or less and going forward).				ut within established eligibility requests (dates of service 30 calendar
Requested Medication	Medication Quantity			Dosing
PA Requirements for Nuviging Is the member 18 years of Please provide the member Narcolepsy  Excessive daytime sleet	f age or older? er's diagnosis a	□ Yes □ No and diagnosis-re		
etc.)? ☐ Yes ( ☐ Shift work sleep disord ☐ Bipolar depression	receiving approposed pocumentations er	riate medical treat required) □ No s being utilized fo	tment for obstructive slee	ep apnea (e.g., PAP, OPT,
□ Other:				

Effective April 1, 2020 Revised April 17, 2023 RXP0010 (4/23)

PA Requirements for Provigil (modafinil):				
Is the member 6 years of age or older? ☐ Yes ☐ No				
Please provide the member's diagnosis and diagnosis-related information:				
□ Narcolepsy				
☐ Excessive daytime sleepiness				
☐ Obstructive sleep apnea with residual excessive daytime sleepiness				
• Is the member receiving appropriate medical treatment for obstructive sleep apnea (e.g., PAP, OPT,				
etc.)? ☐ Yes (Documentation required) ☐ No				
☐ Shift work sleep disorder				
☐ Attention Deficit Hyperactivity Disorder				
☐ Unipolar or bipolar depression				
□ Depression-related fatigue				
☐ Sleep deprivation				
☐ Steinert Myotonic Dystrophy Syndrome				
□ Other:				
PA Requirements for Sunosi (solriamfetrol):				
Is the member 18 years of age or older? ☐ Yes ☐ No				
Please provide the member's diagnosis and diagnosis-related information:				
□ Narcolepsy				
☐ Obstructive sleep apnea with residual excessive daytime sleepiness				
Has the member had a previous trial and failure with any of the following in the past year:				
☐ Modafinil Dates of use:				
☐ Armodafinil Dates of use:				
If <b>no</b> , please document any other medical justification for use:				
ii 110, prease document any other medical justilication of use.				
□ Other:				
PA Requirements for Wakix (pitolisant):				
Is the member 18 years of age or older?   Yes  No				
Please provide the member's diagnosis and diagnosis-related information:				
□ Narcolepsy				
□ Other:				
ы Опібі				

Effective April 1, 2020 Revised April 17, 2023 RXP0010 (4/23)

A Requirements for Xyrem (sodium oxybate):				
<ul><li>□ Narcolepsy with cataplexy and/or</li><li>□ Fibromyalgia</li></ul>	osis and diagnosis-related information:			
_ Amlodipine	Dates of use:			
☐ SSRIs	Medication and dates of use:			
☐ SNRIs	Medication and dates of use:			
☐ Anticonvulsants (gabapentin, pregabalin)	Medication and dates of use:			
☐ NSAIDs and acetaminophen	Dates of use:			
•	medical justification for use as to why not all of the above agents were trialed:			
A Requirements for Xywav (calcium	/magnesium/potassium/sodium oxybates solution):			
Is the member 7 years of age or old Please provide the member's diagno	osis and diagnosis-related information:			
☐ Other:				

## CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

Effective April 1, 2020 Revised April 17, 2023 RXP0010 (4/23)